Disease-Free and Overall Survival Among Patients With Operable HER2-Positive Breast Cancer Treated With Sequential vs Concurrent Chemotherapy: The ACOSOG Z1041 (Alliance) Randomized Clinical Trial

IMPORTANCE: Pathologic complete response rate (pCR), the primary end point of the ACOSOG (American College of Surgeons Oncology Group) Z1041 (Alliance) trial, and disease-free survival (DFS) and overall survival (OS) in women with operable HER2-positive breast cancer are similar between treatment re...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Buzdar, Aman U., Suman, Vera J., Meric-Bernstam, Funda, Leitch, Ann Marilyn, Ellis, Matthew J., Boughey, Judy C., Unzeitig, Gary W., Royce, Melanie E., Hunt, Kelly K.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2018
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6331049/
https://ncbi.nlm.nih.gov/pubmed/30193295
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.3691
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados